Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin Pulse Therapy for Prevention of Acute Exacerbations in Chronic Bronchitis
NCT00473460Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2004
- Primary completion
- Jan 2007
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin in chronic bronchitis (CB) (2 arms), sponsored by Bayer. Primary endpoint: Number of exacerbations after 48 weeks of intermittent pulse treatment. Started Oct 2004; status: completed.
02
Drugs
moxifloxacin
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00473460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00473460.